208 related articles for article (PubMed ID: 35831885)
1. Improvement in insulin sensitivity and prevention of high fat diet-induced liver pathology using a CXCR2 antagonist.
Phillips BE; Lantier L; Engman C; Garciafigueroa Y; Singhi A; Trucco M; Mantzoros C; Wasserman D; Giannoukakis N
Cardiovasc Diabetol; 2022 Jul; 21(1):130. PubMed ID: 35831885
[TBL] [Abstract][Full Text] [Related]
2. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
[TBL] [Abstract][Full Text] [Related]
3. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
[TBL] [Abstract][Full Text] [Related]
4. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
Fu D; Cui H; Zhang Y
Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
[TBL] [Abstract][Full Text] [Related]
5. Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases.
Dewidar B; Mastrototaro L; Englisch C; Ress C; Granata C; Rohbeck E; Pesta D; Heilmann G; Wolkersdorfer M; Esposito I; Reina Do Fundo M; Zivehe F; Yavas A; Roden M
EBioMedicine; 2023 Aug; 94():104714. PubMed ID: 37454552
[TBL] [Abstract][Full Text] [Related]
6. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
Zhou ST; Cui W; Kong L; Yang X
Curr Med Sci; 2022 Jun; 42(3):513-519. PubMed ID: 35451807
[TBL] [Abstract][Full Text] [Related]
8. Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.
Cai X; Fang C; Hayashi S; Hao S; Zhao M; Tsutsui H; Nishiguchi S; Sheng J
J Gastroenterol; 2016 Aug; 51(8):819-29. PubMed ID: 26794005
[TBL] [Abstract][Full Text] [Related]
9. Isoquercitrin attenuates the progression of non-alcoholic steatohepatitis in mice by modulating galectin-3-mediated insulin resistance and lipid metabolism.
Jin HL; Feng XY; Feng SL; Dai L; Zhu WT; Yuan ZW
Phytomedicine; 2024 Jan; 123():155188. PubMed ID: 38056146
[TBL] [Abstract][Full Text] [Related]
10. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice.
Brachs S; Winkel AF; Tang H; Birkenfeld AL; Brunner B; Jahn-Hofmann K; Margerie D; Ruetten H; Schmoll D; Spranger J
Mol Metab; 2016 Nov; 5(11):1072-1082. PubMed ID: 27818933
[TBL] [Abstract][Full Text] [Related]
12.
Wollman A; Daniel T; Rosenzweig T
Nutrients; 2019 Dec; 11(12):. PubMed ID: 31847157
[TBL] [Abstract][Full Text] [Related]
13. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122.
Chai C; Cox B; Yaish D; Gross D; Rosenberg N; Amblard F; Shemuelian Z; Gefen M; Korach A; Tirosh O; Lanton T; Link H; Tam J; Permyakova A; Ozhan G; Citrin J; Liao H; Tannous M; Hahn M; Axelrod J; Arretxe E; Alonso C; Martinez-Arranz I; Betés PO; Safadi R; Salhab A; Amer J; Tber Z; Mengshetti S; Giladi H; Schinazi RF; Galun E
Gastroenterology; 2020 Sep; 159(3):999-1014.e9. PubMed ID: 32450149
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue.
Falkevall A; Mehlem A; Folestad E; Ning FC; Osorio-Conles Ó; Radmann R; de Hollanda A; Wright SD; Scotney P; Nash A; Eriksson U
J Hepatol; 2023 May; 78(5):901-913. PubMed ID: 36717026
[TBL] [Abstract][Full Text] [Related]
15. The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis.
Mulder P; van den Hoek AM; Kleemann R
PLoS One; 2017; 12(1):e0169740. PubMed ID: 28076416
[TBL] [Abstract][Full Text] [Related]
16. Induction of steatohepatitis (NASH) with insulin resistance in wildtype B6 mice by a western-type diet containing soybean oil and cholesterol.
Henkel J; Coleman CD; Schraplau A; Jӧhrens K; Weber D; Castro JP; Hugo M; Schulz TJ; Krämer S; Schürmann A; Püschel GP
Mol Med; 2017 May; 23():70-82. PubMed ID: 28332698
[TBL] [Abstract][Full Text] [Related]
17. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
[TBL] [Abstract][Full Text] [Related]
18. Bicyclol alleviates high-fat diet-induced hepatic ER stress- and autophagy-associated non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in mice.
Jia S; Jin L; Cheng X; Wu J; Yao X; Shao J; Zhang C; Cen D; Cheng B; Wang J; Chen L; Yao X
Drug Dev Ind Pharm; 2022 Jun; 48(6):247-254. PubMed ID: 35875932
[TBL] [Abstract][Full Text] [Related]
19. Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor γ.
Tsujimoto S; Kishina M; Koda M; Yamamoto Y; Tanaka K; Harada Y; Yoshida A; Hisatome I
Int J Mol Med; 2016 Sep; 38(3):721-8. PubMed ID: 27431935
[TBL] [Abstract][Full Text] [Related]
20. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.
Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH
Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
